Hepamerz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-Ornithine l-Aspartate) ## Overview Hepamerz is a combination of two amino acids, l-ornithine and l-aspartate. It is thought to work by promoting the detoxification of ammonia in the liver and the reduction of nitrogen in the body. ## Primary Indications * Treatment of latent and manifest hepatic encephalopathy (HE). ## Adult Dosing * **Oral:** Typically 3 to 6 grams (e.g., 1 to 2 sachets) three times daily. The total daily dose should not exceed 18 grams. * **Intravenous (IV):** Typically 5 grams (1 ampoule) dissolved in 500 mL of infusion solution (e.g., 5% dextrose or Ringer's lactate) administered over 30-60 minutes, twice daily. Dosing can be adjusted based on severity of HE and patient response. Local protocols may guide specific IV dosing and infusion rates. ## Pediatric Dosing * Limited data available. Use is generally at the discretion of the prescriber and based on clinical judgment. ## Dose Adjustments * No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is metabolized in the liver and kidneys. However, caution is advised in patients with severe renal impairment. ## Contraindications * Known hypersensitivity to l-ornithine l-aspartate or any of its components. * Severe kidney disease. ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea. * **General:** Fatigue, headache, dizziness. * Rarely: Allergic reactions. ## Key Drug Interactions * No significant drug interactions are well-established. ## Monitoring * Monitor for signs and symptoms of hepatic encephalopathy. * Electrolytes and renal function may be monitored periodically, especially in patients with underlying renal compromise. ## Clinical Pearls * Hepamerz may be more effective in patients with cirrhosis and HE. * Oral formulations are typically used for chronic management or milder forms of HE, while IV formulations are used for more acute or severe presentations. * Treatment duration depends on the severity of HE and patient response. --- *Disclaimer: This information is intended for clinical professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant guidelines before administering any medication.*